117 related articles for article (PubMed ID: 11291253)
1. Cost-effectiveness of combined interferon and ribavirin versus interferon alone.
Koff RS
Clin Liver Dis; 1999 Nov; 3(4):827-41. PubMed ID: 11291253
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of treatment for chronic hepatitis C.
Koff RS
J Hepatol; 1999; 31 Suppl 1():255-8. PubMed ID: 10622598
[TBL] [Abstract][Full Text] [Related]
3. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
4. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
[TBL] [Abstract][Full Text] [Related]
5. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.
Cummings KJ; Lee SM; West ES; Cid-Ruzafa J; Fein SG; Aoki Y; Sulkowski MS; Goodman SN
JAMA; 2001 Jan; 285(2):193-9. PubMed ID: 11176813
[TBL] [Abstract][Full Text] [Related]
6. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.
Sennfält K; Reichard O; Hultkrantz R; Wong JB; Jonsson D
Scand J Gastroenterol; 2001 Aug; 36(8):870-6. PubMed ID: 11495084
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
Shepherd J; Waugh N; Hewitson P
Health Technol Assess; 2000; 4(33):1-67. PubMed ID: 11134916
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.
Younossi ZM; Singer ME; McHutchison JG; Shermock KM
Hepatology; 1999 Nov; 30(5):1318-24. PubMed ID: 10534357
[TBL] [Abstract][Full Text] [Related]
10. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security.
Siebert U; Sroczynski G; ;
Int J Technol Assess Health Care; 2005; 21(1):55-65. PubMed ID: 15736515
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
13. Management of interferon relapsers.
Jacobson I
Am J Med; 1999 Dec; 107(6B):62S-66S. PubMed ID: 10653460
[TBL] [Abstract][Full Text] [Related]
14. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
Horváth G; Tolvaj G; Halász T; Stotz G
Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus: standard-of-care treatment.
Pawlotsky JM
Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
[TBL] [Abstract][Full Text] [Related]
16. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
18. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
20. [Future outlook for treatment of chronic hepatitis C: IFN + ribavirin combination therapy].
Iino S
Rinsho Byori; 2001 Aug; 49(8):747-54. PubMed ID: 11573281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
